Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada

Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada

Blog Article

CAR-T cell therapy has significantly improved outcomes for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but challenges such as limited resources, manufacturing timelines, and notable toxicities persist.Bispecific antibodies (BsAbs), including glofitamab Vac Switch Lever and epcoritamab, have demonstrated promising efficacy and represent a new treatment option in patients who are unsuitable for or have relapsed following CAR-T therapy.Bispecific antibodies have a manageable safety profile and are generally more widely accessible than CAR-T cell therapy.

Case discussions in this paper illustrate the potential real-world application of BsAbs, highlighting their role in treating patients who have relapsed after or are unable to undergo CAR-T cell therapy.Overall, glofitamab and epcoritamab represent valuable treatment options in the Engine Components evolving landscape of R/R DLBCL.